On Tuesday, Merck & Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib). The trial met one ...
Despite their renal and cardiovascular protection, GLP-1RA vs SGLT2i carries somewhat higher risks of renal cell carcinoma and urothelial cell carcinoma in adults with type 2 diabetes. The risks of ...
Oct 28 (Reuters) - Merck (MRK.N), opens new tab and Eisai's (4523.T), opens new tab experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived ...
Clear cell renal cell carcinoma (RCC) comprises 80% of all primary kidney malignancies and causes 90% of kidney cancer deaths. But it is notoriously tough to diagnose. RCC is not easily distinguished ...
In this video, Elizabeth Plimack, MD, MS, FASCO, Deputy Director at Fox Chase Cancer Center, discusses future research ...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...
As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...
Kidney cancer is on the verge of becoming a far larger health problem than it currently is, with cases expected to nearly double by 2050 worldwide. That’s the bleak conclusion in a sweeping survey led ...
Hosted on MSN
Quit smoking and drink water, says oncologist: Know these 8 tips to reduce kidney cancer risk
The risk of kidney cancer rises significantly after the age of 40. While genetics and age are key contributors, lifestyle choices also play a critical role in increasing the likelihood of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results